Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + secukinumab
- Development stage
- Unknown
- Lead developer
- Union Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Metformin + secukinumab is a combination therapy being investigated for the treatment of moderate-to-severe plaque psoriasis, particularly in patients who are overweight or obese. Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key pro-inflammatory cytokine involved in the development of psoriatic plaques. Metformin, a biguanide traditionally used for type 2 diabetes, is added to this regimen to potentially enhance therapeutic efficacy by activating AMP-activated protein kinase (AMPK) and improving metabolic parameters, which are often dysregulated in obese psoriasis patients. This combination is currently being evaluated in a Phase 4 clinical trial led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology to assess its impact on clinical outcomes such as PASI75 and IGA scores compared to secukinumab monotherapy.
- Other names
- metformin and secukinumab combinationmetformin + secukinumab
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)IL-17A (Interleukin-17A)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on metformin + secukinumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + secukinumab.